FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590051145> ?p ?o ?g. }

• W2590051145 endingPage "9104" @default.
• W2590051145 startingPage "9104" @default.
• W2590051145 abstract "9104 Background: Anti-cancer therapies such as radiation, cytotoxic chemotherapy, and novel targeted agents may cause a range of dermatologic toxicities (dTs). At present, there are limited data regarding the impact of dTs on dermatologic quality of life (dQoL). We systematically investigated their impact on dQoL in patients seen at the SERIES clinic, a referral center for management of dTs stemming from anti-cancer therapies. Methods: Medical records of patients seen in the dermatology referral clinic for cancer patients at Northwestern University between 9/2007 and 9/2008 were searched for completion of Skindex-16, a dermatology-specific QoL questionnaire. Skindex scores range from 0 (best QoL) to 96 (worst QoL) and measure 3 domains: symptoms, emotions and function. The impact of dTs on the total Skindex score and the scores of each domain were analyzed. Descriptive statistics (means, medians, range) were used to describe scores. Differences in mean scores were evaluated by linear regression. Results: A total of 425 patients were analyzed. EGFRI-associated papulopustular (ppr) rash, HFS/HFSR, nail toxicities, xerosis, fissures, pruritus and alopecia were observed in 26.7%, 12.5%, 9.2%, 31.1%, 5.0%, 18.1%, and 9.4% of patients, respectively. The presence of ppr rash was associated with a greater impact on the mean total, symptoms, emotions, and function domain scores as compared to patients without ppr rash (45.1 vs. 30.4; 11.6 vs. 8.4; 23.4 vs. 16.5; 10.1 vs. 5.6, p<0.001). Similarly, the presence of pruritus was associated with a greater impact on the mean total and all three domains scores (46.5 vs.31.6; 13.5 vs. 8.3; 23.2 vs. 17.2; 9.8 vs. 6.2, p<0.001, =0.003, =0.0008, respectively). Patients (n=32) with ≥ 3 dTs (ppr rash, nail toxicities, xerosis, fissures, and pruritus) had a significantly higher mean total as well as symptoms, emotions and function scores as compared to patients with fewer dTs (47.6, 14.4, 23.4, 9.8, respectively, p<0.001). Conclusions: dTs are associated with diminished dQoL; ppr rash and pruritus appear to have the greatest negative impact. Future emphasis should be placed on developing effective management strategies for dTs in order to minimize the likelihood of reduced dQoL." @default.
• W2590051145 created "2017-03-03" @default.
• W2590051145 creator A5009093707 @default.
• W2590051145 creator A5012974637 @default.
• W2590051145 creator A5014223361 @default.
• W2590051145 creator A5015349477 @default.
• W2590051145 creator A5060346334 @default.
• W2590051145 creator A5061638063 @default.
• W2590051145 creator A5070040522 @default.
• W2590051145 date "2011-05-20" @default.
• W2590051145 modified "2023-09-25" @default.
• W2590051145 title "Quality of life in patients with dermatologic toxicities: Experience from the SERIES clinic." @default.
• W2590051145 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.9104" @default.
• W2590051145 hasPublicationYear "2011" @default.
• W2590051145 type Work @default.
• W2590051145 sameAs 2590051145 @default.
• W2590051145 citedByCount "0" @default.
• W2590051145 crossrefType "journal-article" @default.
• W2590051145 hasAuthorship W2590051145A5009093707 @default.
• W2590051145 hasAuthorship W2590051145A5012974637 @default.
• W2590051145 hasAuthorship W2590051145A5014223361 @default.
• W2590051145 hasAuthorship W2590051145A5015349477 @default.
• W2590051145 hasAuthorship W2590051145A5060346334 @default.
• W2590051145 hasAuthorship W2590051145A5061638063 @default.
• W2590051145 hasAuthorship W2590051145A5070040522 @default.
• W2590051145 hasConcept C121608353 @default.
• W2590051145 hasConcept C126322002 @default.
• W2590051145 hasConcept C159110408 @default.
• W2590051145 hasConcept C16005928 @default.
• W2590051145 hasConcept C2776135927 @default.
• W2590051145 hasConcept C2777673923 @default.
• W2590051145 hasConcept C2778081122 @default.
• W2590051145 hasConcept C2778570526 @default.
• W2590051145 hasConcept C2778847519 @default.
• W2590051145 hasConcept C2779951463 @default.
• W2590051145 hasConcept C512399662 @default.
• W2590051145 hasConcept C71924100 @default.
• W2590051145 hasConceptScore W2590051145C121608353 @default.
• W2590051145 hasConceptScore W2590051145C126322002 @default.
• W2590051145 hasConceptScore W2590051145C159110408 @default.
• W2590051145 hasConceptScore W2590051145C16005928 @default.
• W2590051145 hasConceptScore W2590051145C2776135927 @default.
• W2590051145 hasConceptScore W2590051145C2777673923 @default.
• W2590051145 hasConceptScore W2590051145C2778081122 @default.
• W2590051145 hasConceptScore W2590051145C2778570526 @default.
• W2590051145 hasConceptScore W2590051145C2778847519 @default.
• W2590051145 hasConceptScore W2590051145C2779951463 @default.
• W2590051145 hasConceptScore W2590051145C512399662 @default.
• W2590051145 hasConceptScore W2590051145C71924100 @default.
• W2590051145 hasIssue "15_suppl" @default.
• W2590051145 hasLocation W25900511451 @default.
• W2590051145 hasOpenAccess W2590051145 @default.
• W2590051145 hasPrimaryLocation W25900511451 @default.
• W2590051145 hasRelatedWork W1562571209 @default.
• W2590051145 hasRelatedWork W2007540203 @default.
• W2590051145 hasRelatedWork W2053221007 @default.
• W2590051145 hasRelatedWork W2087948898 @default.
• W2590051145 hasRelatedWork W2507802692 @default.
• W2590051145 hasRelatedWork W2547152897 @default.
• W2590051145 hasRelatedWork W2564643150 @default.
• W2590051145 hasRelatedWork W2884243983 @default.
• W2590051145 hasRelatedWork W4319349993 @default.
• W2590051145 hasRelatedWork W775482203 @default.
• W2590051145 hasVolume "29" @default.
• W2590051145 isParatext "false" @default.
• W2590051145 isRetracted "false" @default.
• W2590051145 magId "2590051145" @default.
• W2590051145 workType "article" @default.